Zobrazeno 1 - 10
of 40
pro vyhledávání: '"Josephina G. Kuiper"'
Autor:
Emily I. Holthuis, Gerard T. Vondeling, Josephina G. Kuiper, Vincent Dezentjé, Mats Rosenlund, Jetty A. Overbeek, Carolien H.M. van Deurzen
Publikováno v:
Breast, Vol 66, Iss , Pp 278-284 (2022)
Background: With the introduction of investigational human epidermal growth factor receptor 2 (HER2) targeting treatments, thorough understanding of breast cancer with different HER2 expression levels is critical. The aim of this study was to compare
Externí odkaz:
https://doaj.org/article/f27723d95f8e4f1087383b9359ad986c
Risk of heart failure among colon and rectal cancer survivors: a population‐based case–control study
Autor:
Josephina G. Kuiper, Myrthe P.P. vanHerk‐Sukel, Valery E.P.P. Lemmens, Mathijs J. Kuiper, Ernst J. Kuipers, Ron M.C. Herings
Publikováno v:
ESC Heart Failure, Vol 9, Iss 4, Pp 2139-2146 (2022)
Abstract Aims This population‐based case–control study aims to investigate the occurrence of heart failure (HF) among colon and rectal cancer survivors compared with a cancer‐free control population taking into account pre‐existing cardiovasc
Externí odkaz:
https://doaj.org/article/13c60cb7fbeb40718ba3be781e942ad4
Autor:
Josephina G. Kuiper, Myrthe P. P. van Herk-Sukel, Valery E. P. P. Lemmens, Ernst J. Kuipers, Ron M. C. Herings
Publikováno v:
BMC Family Practice, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Timely recognition of colorectal cancer related symptoms is essential to reduce time to diagnosis. This study aims to investigate the primary healthcare use preceding a colorectal cancer diagnosis. Methods From a cohort of linked
Externí odkaz:
https://doaj.org/article/fc1ac27ea50344f3a07c7bf0730f551d
Autor:
Katja A. Oppelt, Josephina G. Kuiper, Ylenia Ingrasciotta, Valentina Ientile, Ron M. C. Herings, Michele Tari, Gianluca Trifirò, Ulrike Haug
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Introduction: Biologics were approved for the treatment of advanced colorectal cancer (CRC) based on favorable benefit-risk-assessments from randomized controlled trials (RCTs), but evidence on their use in the real-world setting is scarce. Based on
Externí odkaz:
https://doaj.org/article/9d14946394834ea08de389b1eabf0e07
Autor:
Alejandro Arana, Anton Pottegård, Josephina G Kuiper, Helen Booth, Johan Reutfors, Brian Calingaert, Lars Christian Lund, Elizabeth Crellin, Marcus Schmitt-Egenolf, James A Kaye, Karin Gembert, Kenneth J Rothman, Helle Kieler, Daniel Dedman, Eline Houben, Lia Gutiérrez, Jesper Hallas, Susana Perez-Gutthann
Publikováno v:
Clinical Epidemiology
Alejandro Arana,1 Anton Pottegård,2 Josephina G Kuiper,3 Helen Booth,4 Johan Reutfors,5 Brian Calingaert,6 Lars Christian Lund,2 Elizabeth Crellin,4 Marcus Schmitt-Egenolf,5,7 James A Kaye,8 Karin Gembert,5 Kenneth J Rothman,8 Helle Kieler,5 Danie
Autor:
Josephina G. Kuiper, Myrthe P.P. van Herk‐Sukel, Valery E.P.P. Lemmens, Mathijs J. Kuiper, Ernst J. Kuipers, Ron M.C. Herings
Publikováno v:
Kuiper, J G, van Herk-Sukel, M P P, Lemmens, V E P P, Kuiper, M J, Kuipers, E J & Herings, R M C 2022, ' Risk of heart failure among colon and rectal cancer survivors : a population-based case–control study ', ESC Heart Failure, vol. 9, no. 4, pp. 2139-2146 . https://doi.org/10.1002/ehf2.13923
ESC heart failure, 9(4), 2139-2146. The Heart Failure Association of the European Society of Cardiology
ESC Heart Failure, 9(4), 2139-2146. The Heart Failure Association of the European Society of Cardiology
ESC heart failure, 9(4), 2139-2146. The Heart Failure Association of the European Society of Cardiology
ESC Heart Failure, 9(4), 2139-2146. The Heart Failure Association of the European Society of Cardiology
Aims: This population-based case–control study aims to investigate the occurrence of heart failure (HF) among colon and rectal cancer survivors compared with a cancer-free control population taking into account pre-existing cardiovascular risk fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::312b1b4b82d67cf3c5e5087e27a4b84a
https://research.vumc.nl/en/publications/01032252-7097-43bc-9822-133806cd05c6
https://research.vumc.nl/en/publications/01032252-7097-43bc-9822-133806cd05c6
Autor:
Ron M. C. Herings, Myrthe P. P. van Herk-Sukel, Valery E.P.P. Lemmens, Eric Fliers, Max Nieuwdorp, Ernst J. Kuipers, Aline C. Fenneman, Anne H van der Spek, Elena Rampanelli, Josephina G. Kuiper
Publikováno v:
Endocrine Connections, 11(1):e210463. Bioscientifica Ltd
Endocrine connections, 11(1):e210463. BioScientifica Ltd.
Endocrine Connections
Kuiper, J G, Fenneman, A C, van der Spek, A H, Rampanelli, E, Nieuwdorp, M, van Herk-Sukel, M P P, Lemmens, V, Kuipers, E J, Herings, R M C & Fliers, E 2022, ' Levothyroxine use and the risk of colorectal cancer : a large population-based case–control study ', Endocrine Connections, vol. 11, no. 1, e210463 . https://doi.org/10.1530/EC-21-0463
Endocrine Connections, Vol 11, Iss 1, Pp 1-8 (2022)
Endocrine Connections, 11(1):e210463. BioScientifica Ltd.
Endocrine connections, 11(1):e210463. BioScientifica Ltd.
Endocrine Connections
Kuiper, J G, Fenneman, A C, van der Spek, A H, Rampanelli, E, Nieuwdorp, M, van Herk-Sukel, M P P, Lemmens, V, Kuipers, E J, Herings, R M C & Fliers, E 2022, ' Levothyroxine use and the risk of colorectal cancer : a large population-based case–control study ', Endocrine Connections, vol. 11, no. 1, e210463 . https://doi.org/10.1530/EC-21-0463
Endocrine Connections, Vol 11, Iss 1, Pp 1-8 (2022)
Endocrine Connections, 11(1):e210463. BioScientifica Ltd.
Objective Whether an association between oral levothyroxine use, leading to supraphysiological exposure of the colon to thyroid hormones, and risk of colorectal cancer exists in humans is unclear. We therefore aimed to assess whether the use of levot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e83ee17d3a98af2bf6bf59dbc5d3c446
https://pure.eur.nl/en/publications/e037881f-5bf5-401f-acd8-6b04aa8fe29c
https://pure.eur.nl/en/publications/e037881f-5bf5-401f-acd8-6b04aa8fe29c
Autor:
Josephina G. Kuiper, Mieke J. Aarts, Eric C T Geijteman, Lia van Zuylen, Heidi Fransen, Edwin J. Brokaar, Peter W. A. Kunst, Laurien Ham, Loes E. Visser, Natasja J H Raijmakers
Publikováno v:
Ham, L, Geijteman, E C T, Aarts, M J, Kuiper, J G, Kunst, P W A, Raijmakers, N J H, Visser, L E, van Zuylen, L, Brokaar, E J & Fransen, H P 2022, ' Use of potentially inappropriate medication in older patients with lung cancer at the end of life ', Journal of Geriatric Oncology, vol. 13, no. 1, pp. 53-59 . https://doi.org/10.1016/j.jgo.2021.07.009
Journal of Geriatric Oncology, 13(1), 53-59. Elsevier Ltd.
Journal of Geriatric Oncology, 13(1), 53-59. Elsevier Ltd
Journal of Geriatric Oncology, 13(1), 53-59. Elsevier Ltd.
Journal of Geriatric Oncology, 13(1), 53-59. Elsevier Ltd
OBJECTIVES: Medications at the end of life should be used for symptom control. Medications which potential adverse effects outweigh their expected benefits are called 'potentially inappropriate medications' (PIMs). PIMs are related with adverse drug
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4adac0869d0c4fb4161460ad6ac81c55
https://research.vumc.nl/en/publications/a51a3442-26c7-48fd-92be-7ee6def44dc4
https://research.vumc.nl/en/publications/a51a3442-26c7-48fd-92be-7ee6def44dc4
Autor:
Josephina G. Kuiper, Peter H. Bisschop, Anneke Wijbenga, Eric Fliers, Joke C. Korevaar, Marijke Janssens, Johan P. De Graaf, Liset van Dijk, Ron M. C. Herings, Bruce H. R. Wolffenbuttel, Eugène van Puijenbroek, Thera P. Links, E. Houben, Karin Hek, Annemieke Horikx, L. Flinterman, Rietje Meijer, Anton A.M. Franken
Publikováno v:
Thyroid, 30(6), 821-828. Mary Ann Liebert Inc.
Flinterman, L E, Kuiper, J G, Korevaar, J C, van Dijk, L, Hek, K, Houben, E, Herings, R, Franken, A A M, de Graaf, J P, Horikx, A, Janssens, M, Meijer, R, Wijbenga, A, van Puijenbroek, E, Wolffenbuttel, B H R, Links, T P, Bisschop, P H & Fliers, E 2020, ' Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study ', Thyroid, vol. 30, no. 6, pp. 821-828 . https://doi.org/10.1089/thy.2019.0414
Thyroid, 30(6), 821-828. MARY ANN LIEBERT, INC
Flinterman, L E, Kuiper, J G, Korevaar, J C, van Dijk, L, Hek, K, Houben, E, Herings, R, Franken, A A M, de Graaf, J P, Horikx, A, Janssens, M, Meijer, R, Wijbenga, A, van Puijenbroek, E, Wolffenbuttel, B H R, Links, T P, Bisschop, P H & Fliers, E 2020, ' Impact of a Forced Dose-Equivalent Levothyroxine Brand Switch on Plasma Thyrotropin: A Cohort Study ', Thyroid, vol. 30, no. 6, pp. 821-828 . https://doi.org/10.1089/thy.2019.0414
Thyroid, 30(6), 821-828. MARY ANN LIEBERT, INC
Background: Patients with primary hypothyroidism are treated with levothyroxine (LT4) to normalize their serum thyrotropin (TSH). Finding the optimal dosage is a long-lasting process, and a small change can have major impact. Currently, limited data
Publikováno v:
Clinical Epidemiology. 12:415-422
The PHARMO Database Network provides a unique opportunity to gain insight in the complete patient journey and healthcare in the Netherlands. The PHARMO Database Network is a population-based network of electronic healthcare databases and combines ano